APA (7th ed.) Citation

ATM, L., & SI, O. (2024, May). LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. Lung Cancer: Targets and Therapy.

Chicago Style (17th ed.) Citation

ATM, Lee, and Ou SI. "LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC." Lung Cancer: Targets and Therapy May. 2024.

MLA (9th ed.) Citation

ATM, Lee, and Ou SI. "LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC." Lung Cancer: Targets and Therapy, May. 2024.